September 2015September 2015
New Product - Privigen
Privigen (normal immunoglobulin (human)) is a solution of human normal immunoglobulin for intravenous infusion. Adequate doses of human normal immunoglobulin may restore abnormally low IgG levels to the normal range. The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects. Privigen is indicated as replacement therapy in the following conditions. Primary immunodeficiency diseases; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia; and recurrent infections and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. Privigen is indicated as immunomodulatory therapy in idiopathic thrombocytopenic purpura in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain‑Barré syndrome; Kawasaki disease; chronic inflammatory demyelinating polyneuropathy; multifocal motor neuropathy; myasthenia gravis exacerbations; Lambert‑Eaton myasthenic syndrome and stiff person syndrome. It is contraindicated in hypersensitivity to homologous immunoglobulins, especially in the very rare cases of IgA deficiency when the patient has antibodies against IgA, and in patients with hyperprolinaemia. Privigen is presented as a 10% (100 g/L) solution for intravenous infusion in 50 mL (5 g/50 mL), 100 mL (10 g/100 mL), 200 mL (20 g/200 mL) and 400 mL (40 g/400 mL) bottles.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au